After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!

Quick Order

Text Size:AAA

Cynomolgus EWI-F / PTGFRN Protein (His Tag)

DatasheetSpecific ReferencesReviewsRelated ProductsProtocols
Cynomolgus PTGFRN Protein Product Information
Protein Construction:A DNA sequence encoding the cynomolgus PTGFRN (H9ERH4) (Met1-Lys830) was expressed with a polyhistidine tag at the C-terminus.
Expressed Host:Human Cells
Shipping:In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Cynomolgus PTGFRN Protein QC Testing
Purity:> 95 % as determined by SDS-PAGE
Endotoxin:< 1.0 EU per μg of the protein as determined by the LAL method
Stability:Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N Terminal:Val 26
Molecule Mass:The recombinant cynomolgus PTGFRN comprises 816 amino acids and has a calculated molecular mass of 91.5 KDa. The apparent molecular mass of it is approximately 96-106 KDa in SDS-PAGE under reducing conditions.
Formulation:Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
Cynomolgus PTGFRN Protein Usage Guide
Storage:Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution:A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Other PTGFRN Recombinant Protein Products
EWI-F / PTGFRN Background

EWI-F, also known as PTGFRN, is inversely related to the loss of CD9. Its expression correlates with the metastatic status of hLT (n=55). EWI-F inhibits the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, by decreasing the receptor number rather than the affinity constant. EWI-F expression positively correlates with the metastatic status of hLT, and that the upregulation of EWI-F expression could be one of the mechanisms underlying the loss of CD9 in solid tumours.

Cynomolgus EWI-F / PTGFRN References
  • Stipp C S. et al., 2001, J Biol Chem. 276 (7): 4853-62.
  • Charrin S. et al., 2001, J Biol Chem. 276 (17): 14329-37.
  • Orlicky DJ. et al., 1996, Hum Genet. 97 (5): 655-8.
  • Product nameProduct name
    Size / Price
    Catalog: 90276-C08H-100
    List Price:   (Save )
    Price:      [How to order]
    AvailabilityIn StockShipping instructions